Pharmaceuticals Add Strength to Lobbying
Pharmaceutical companies and associations
have reported large increases in their lobby spending during the first quarter of 2013. Most have been lobbying in the areas of budget/appropriations; copyright/patents/trademarks; health; Medicare/Medicaid; and trade. For details on issues and specific bills see PhRMA’s report.
The Pharmaceutical Research & Manufacturers spent $5,270,000 – up from $4,940,000 in the last quarter of 2012.
Merck & Company spent $4,190,000 – up from $1,190,000.
Novartis Corporation spent $3,290,000 – up from 1,212,000.
Pfizer Inc. spent $2,870,000 – up from $1,730,000.
Eli Lilly & Company spent $2,610,000 – up from $2,055,000.
Sanofi-Aventis spent $1,800,000 – up from $1,590,000.
Teva Pharmaceuticals spent $1,570,000 – up from $750,000.
GlaxoSmithKline spent $1,510,000 – up from $1,370,000.
Johnson & Johsnon Inc. spent $1,430,000 – up from $880,000.
Amgen USA Inc. spent $2,290,000 – up from $2,250,000.
Bayer Corporation spent $1,820,000 – up from $1,150,000.
(more)
AstraZeneca Pharmaceuticals LP spent $1,210,000 – up from $340,000.
Genentech Inc. spent $1,202,000 – up from $1,129,400.
Boehringer Ingelheim Pharmaceuticals Inc. spent $1,013,000 – up from $590,000.
EMD Serono Inc. spent $850,000 – up from $720,000.
Bristol-Myers Squibb Company spent $830,000 – down from $1,280,000
Abbott Laboratories spent $500,000 – down from $840,000.
